Products

  1. Home
  2. Products
  3. Bone & Mineral Metabolism
  4. IDK® anti-htTG sIgA ELISA (Stool)

IDK® anti-htTG sIgA ELISA (Stool)

Item #: KR9393 Categories: ,

$372.00

Available with Lead Time!

Method: ELISA
Sample Type (Matrix): Stool
Sample Volume: 15 mg
Species: Human
Incubation time: 2h 15m
Standard Range: cut off
Size: 96 wells
Regulatory Status: For research use only in the U.S.
Kit Manual: Download

The IDK® anti-htTG sIgA ELISA is an enzyme immunoassay intended for the quantitative determination of anti-human tissue Transglutaminase sIgA antibodies in stool.

For research use only. Not for use in diagnostic procedures.

For Laboratory Professional Use Only.

The IDK® anti-htTG sIgA ELISA (Stool) is compatible with our IDK Extract® Stool Sample Preparation System.

This is the RUO version of Immundiagnostik part number K 9393.

Test Principle of the IDK® anti-htTG sIgA ELISA

The IDK® anti-htTG sIgA ELISA is designed for the quantitative determination of anti-htTG sIgA antibodies in feces.

In the first incubation step, the anti-htTG sIgA antibodies in the sample are bound to their antigen (human recombinant transglutaminase), which is immobilized on the surface of the microtiter plates. To remove all unbound foreign substances, a washing step is carried out.

In a second incubation step, a peroxidase-labeled sIgA antibody is added. After another washing step, to remove all unbound antibodies, the solid phase is incubated with the substrate, tetramethylbenzidine.

An acidic stop solution is then added to stop the reaction. The color converts from blue to yellow. The intensity of the yellow color is directly proportional to the amount of bound antibodies and can be determined photometrically at 450 nm. The results are evaluated by comparison with a cut-off value.

 

Additional information

Weight 35.5 oz
Dimensions 6.5 × 10 × 4.5 in
Social media & sharing icons powered by UltimatelySocial

Become an IDK Insider!

Join our mailing list to receive the latest news and updates from Immundiagnostik, Inc.

 
 
 
 

You have Successfully Subscribed!